{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:17:16Z","timestamp":1791346636109,"version":"4.3.1"},"reference-count":259,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001459","name":"Government of Singapore Ministry of Education","doi-asserted-by":"publisher","award":["MOE 2019-T3\\u20131-012"],"award-info":[{"award-number":["MOE 2019-T3\\u20131-012"]}],"id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001381","name":"National Research Foundation","doi-asserted-by":"publisher","award":["CRP30\\u20132023-0004"],"award-info":[{"award-number":["CRP30\\u20132023-0004"]}],"id":[{"id":"10.13039\/501100001381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014066","name":"Naval Medical Research Center\u2014Asia","doi-asserted-by":"publisher","award":["FLCG23may-0032"],"award-info":[{"award-number":["FLCG23may-0032"]}],"id":[{"id":"10.13039\/100014066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jconrel.2026.114841","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:11:51Z","timestamp":1774051911000},"page":"114841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Retinal gene therapies for inherited ocular diseases: Translational delivery strategies from bench to bedside"],"prefix":"10.1016","volume":"394","author":[{"given":"Soheil","family":"Haddadzadegan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikta","family":"Mehdizdeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina T.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Miserez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.114841_bb0005","doi-asserted-by":"crossref","first-page":"7014745","DOI":"10.1155\/joph\/7014745","article-title":"Systematic identification of candidate genes for inherited retinal disease gene therapy integrating worldwide IRD cohort and single-cell analysis","volume":"2025","author":"Wang","year":"2025","journal-title":"J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2026.114841_bb0010","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1073\/pnas.1913179117","article-title":"Worldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases","volume":"117","author":"Hanany","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb0015","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/bjophthalmol-2016-309975","article-title":"Leber congenital amaurosis\/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions","volume":"101","author":"Kumaran","year":"2017","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2026.114841_bb0020","series-title":"Cell-Based Therapy for Degenerative Retinal Disease","first-page":"29","article-title":"Clinical and pathological features of selected human retinal degenerative diseases","author":"Hogden","year":"2019"},{"key":"10.1016\/j.jconrel.2026.114841_bb0025","first-page":"117","article-title":"Genes and genetics in eye diseases: a genomic medicine approach for investigating hereditary and inflammatory ocular disorders","volume":"11","author":"Singh","year":"2018","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2026.114841_bb0030","series-title":"advances in vision research, Volume III: Genetic Eye Research around the Globe","first-page":"153","article-title":"Genome analysis for inherited retinal disease: the state of the art","author":"Oprych","year":"2021"},{"key":"10.1016\/j.jconrel.2026.114841_bb0035","doi-asserted-by":"crossref","first-page":"491","DOI":"10.59249\/HWID7537","article-title":"Ocular gene therapy: An overview of viral vectors, immune responses, and future directions","volume":"97","author":"Banou","year":"2024","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.jconrel.2026.114841_bb0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/bioengineering9010041","article-title":"Targeting ocular drug delivery: an examination of local anatomy and current approaches","volume":"9","author":"Dosmar","year":"2022","journal-title":"Bioengineering"},{"key":"10.1016\/j.jconrel.2026.114841_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2024.105785","article-title":"Insights into ocular therapeutics: a comprehensive review of anatomy, barriers, diseases and nanoscale formulations for targeted drug delivery","volume":"97","author":"Chandel","year":"2024","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.jconrel.2026.114841_bb0050","doi-asserted-by":"crossref","DOI":"10.1088\/0957-0233\/20\/10\/104020","article-title":"Review of biomedical optical imaging\u2014a powerful, non-invasive, non-ionizing technology for improving in vivo diagnosis","volume":"20","author":"Balas","year":"2009","journal-title":"Meas. Sci. Technol."},{"key":"10.1016\/j.jconrel.2026.114841_bb0055","doi-asserted-by":"crossref","first-page":"2407173","DOI":"10.1002\/adfm.202407173","article-title":"The future of nanomaterials tackling the challenge of delivering nucleic acids to the retina","volume":"35","author":"Hurst","year":"2025","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2026.114841_bb0060","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12951-025-03095-6","article-title":"Frontier applications of retinal nanomedicine: progress, challenges and perspectives","volume":"23","author":"Tang","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2026.114841_bb0065","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40291-020-00475-6","article-title":"Voretigene neparvovec: a review in RPE65 mutation-associated inherited retinal dystrophy","volume":"24","author":"Kang","year":"2020","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.jconrel.2026.114841_bb0070","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/14712598.2020.1740676","article-title":"Voretigene neparvovec-rzyl for treatment of RPE65-mediated inherited retinal diseases: a model for ocular gene therapy development","volume":"20","author":"Ciulla","year":"2020","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.jconrel.2026.114841_bb0075","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1038\/s41433-024-03065-6","article-title":"Voretigene neparvovec for inherited retinal dystrophy due to RPE65 mutations: a scoping review of eligibility and treatment challenges from clinical trials to real practice","volume":"38","author":"Testa","year":"2024","journal-title":"Eye"},{"key":"10.1016\/j.jconrel.2026.114841_bb0080","article-title":"Lipid nanoparticle technology-mediated therapeutic gene manipulation in the eyes","volume":"35","author":"Wang","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.114841_bb0085","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/14712598.2022.2012148","article-title":"Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders","volume":"22","author":"Marrone","year":"2022","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.jconrel.2026.114841_bb0090","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3390\/biomedicines13020365","article-title":"Looking to the future of viral vectors in ocular gene therapy: clinical review","volume":"13","author":"Kharisova","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.jconrel.2026.114841_bb0095","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s12325-020-01243-y","article-title":"An economic evaluation of voretigene neparvovec for the treatment of biallelic RPE65-mediated inherited retinal dystrophies in the UK","volume":"37","author":"Viriato","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jconrel.2026.114841_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261897","article-title":"Blindness and visual impairment in Central Europe","volume":"17","author":"Glatz","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2026.114841_bb0105","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/13816810.2021.1913610","article-title":"Inherited retinal diseases are the most common cause of blindness in the working-age population in Australia","volume":"42","author":"Heath Jeffery","year":"2021","journal-title":"Ophthalmic Genet."},{"key":"10.1016\/j.jconrel.2026.114841_bb0110","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2147\/OPTH.S241928","article-title":"The impact of inherited retinal diseases in the Republic of Ireland (ROI) and the United Kingdom (UK) from a cost-of-illness perspective","author":"Galvin","year":"2020","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.jconrel.2026.114841_bb0115","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3390\/biom13020271","article-title":"Cellular and molecular mechanisms of pathogenesis underlying inherited retinal dystrophies","volume":"13","author":"Manley","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.jconrel.2026.114841_bb0120","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.3390\/jcm12175620","article-title":"Retinitis pigmentosa masquerades: case series and review of the literature","volume":"12","author":"Thenappan","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2026.114841_bb0125","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1177\/1120672121990578","article-title":"Imaging in inherited retinal disorders","volume":"31","author":"Muftuoglu","year":"2021","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2026.114841_bb0130","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3390\/ijms23020726","article-title":"Primary and secondary cone cell death mechanisms in inherited retinal diseases and potential treatment options","volume":"23","author":"Brunet","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb0135","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/biom14080903","article-title":"Gene therapy for retinitis pigmentosa: current challenges and new progress","volume":"14","author":"Liu","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.jconrel.2026.114841_bb0140","doi-asserted-by":"crossref","first-page":"25584","DOI":"10.31083\/FBL25584","article-title":"Exploring molecular pathways in refractive errors associated with inherited retinal dystrophies","volume":"30","author":"D\u2019Esposito","year":"2025","journal-title":"Front. Biosci. Landmark"},{"key":"10.1016\/j.jconrel.2026.114841_bb0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/IIO.0000000000000377","article-title":"Genes and gene therapy in inherited retinal disease","volume":"61","author":"Shughoury","year":"2021","journal-title":"Int. Ophthalmol. Clin."},{"key":"10.1016\/j.jconrel.2026.114841_bb0150","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/13816810.2016.1275021","article-title":"Leber congenital amaurosis, from darkness to light: an ode to Irene Maumenee","volume":"38","author":"Coussa","year":"2017","journal-title":"Ophthalmic Genet."},{"key":"10.1016\/j.jconrel.2026.114841_bb0155","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1600-0420.2006.00751.x","article-title":"From basic to clinical research: a journey with the retina, the retinal pigment epithelium, the cornea, age-related macular degeneration and hereditary degenerations, as seen in the rear view mirror","volume":"84","author":"Nilsson","year":"2006","journal-title":"Acta Ophthalmol. Scand."},{"key":"10.1016\/j.jconrel.2026.114841_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094534","article-title":"An update on gene therapy for inherited retinal dystrophy: experience in Leber congenital amaurosis clinical trials","volume":"22","author":"Chiu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb0165","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041307","article-title":"Lessons learned from the development of the first FDA-approved gene therapy drug, voretigene neparvovec-rzyl","volume":"13","author":"Bennett","year":"2023","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.jconrel.2026.114841_bb0170","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1080\/14712598.2018.1513486","article-title":"Stargardt macular dystrophy and evolving therapies","volume":"18","author":"Hussain","year":"2018","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.jconrel.2026.114841_bb0175","series-title":"Atlas of Inherited Retinal Diseases","first-page":"139","article-title":"Stargardt disease","author":"Tsang","year":"2018"},{"key":"10.1016\/j.jconrel.2026.114841_bb0180","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1076\/opge.24.2.75.13996","article-title":"The gene for Stargardt disease, ABCA4, is a major retinal gene: a mini-review","volume":"24","author":"Koenekoop","year":"2003","journal-title":"Ophthalmic Genet."},{"key":"10.1016\/j.jconrel.2026.114841_bb0185","series-title":"Inflammation and Retinal Disease: Complement Biology and Pathology","first-page":"105","article-title":"The ATP-binding cassette transporter ABCA4: structural and functional properties and role in retinal disease","author":"Tsybovsky","year":"2010"},{"key":"10.1016\/j.jconrel.2026.114841_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/nu13113987","article-title":"Vitamin a transporters in visual function: a mini review on membrane receptors for dietary vitamin a uptake, storage, and transport to the eye","volume":"13","author":"Martin Ask","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.jconrel.2026.114841_bb0195","doi-asserted-by":"crossref","first-page":"10303","DOI":"10.1074\/jbc.272.15.10303","article-title":"The 220-kDa rim protein of retinal rod outer segments is a member of the ABC transporter superfamily","volume":"272","author":"Illing","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2026.114841_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1010129","article-title":"Rare and common variants in ROM1 and PRPH2 genes trans-modify Stargardt\/ABCA4 disease","volume":"18","author":"Zernant","year":"2022","journal-title":"PLoS Genet."},{"key":"10.1016\/j.jconrel.2026.114841_bb0205","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041288","article-title":"X-linked retinoschisis","volume":"13","author":"Ku","year":"2023","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.jconrel.2026.114841_bb0210","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.preteyeres.2011.12.002","article-title":"X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms","volume":"31","author":"Molday","year":"2012","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2026.114841_bb0215","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3390\/pharmaceutics14010134","article-title":"Topical drug delivery to the posterior segment of the eye","volume":"14","author":"L\u00f6scher","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114841_bb0220","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.3390\/ijms20246132","article-title":"Contribution of mucins towards the physical properties of the tear film: a modern update","volume":"20","author":"Georgiev","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb0225","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3390\/pharmaceutics15020470","article-title":"Biopolymers in mucoadhesive eye drops for treatment of dry eye and allergic conditions: application and perspectives","volume":"15","author":"Ra\u010di\u0107","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114841_bb0230","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/bs.pmbts.2015.04.001","article-title":"Overview of the cornea: structure, function, and development","volume":"134","author":"Eghrari","year":"2015","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb0235","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3390\/polym10111221","article-title":"Strategies for improving ocular drug bioavailability and corneal wound healing with chitosan-based delivery systems","volume":"10","author":"Irimia","year":"2018","journal-title":"Polymers (Basel)."},{"key":"10.1016\/j.jconrel.2026.114841_bb0240","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1021\/js9802594","article-title":"Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye","volume":"87","author":"Prausnitz","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb0245","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1208\/s12249-023-02516-9","article-title":"Ocular drug delivery: a comprehensive review","volume":"24","author":"Ahmed","year":"2023","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2026.114841_bb0250","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2174\/1570180819999220204110306","article-title":"Recent advances in drug design and delivery across biological barriers using computational models","volume":"19","author":"Vanshita","year":"2022","journal-title":"Lett. Drug Des. Discov."},{"key":"10.1016\/j.jconrel.2026.114841_bb0255","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3390\/biomedicines10061458","article-title":"Self-organization of the retina during eye development, retinal regeneration in vivo, and in retinal 3D organoids in vitro","volume":"10","author":"Grigoryan","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.jconrel.2026.114841_bb0260","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-vision-100820-083937","article-title":"The retina-based visual cycle","volume":"10","author":"Sato","year":"2024","journal-title":"Annu. Rev. Vis. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/gels8020082","article-title":"Drug delivery challenges and current progress in nanocarrier-based ocular therapeutic system","volume":"8","author":"Akhter","year":"2022","journal-title":"Gels"},{"key":"10.1016\/j.jconrel.2026.114841_bb0270","article-title":"Retinal pigment epithelium as a barrier in drug permeation and as a target of non-viral gene delivery (Verkkokalvon pigmenttiepiteeli l\u00e4\u00e4keainel\u00e4p\u00e4isevyyden esteen\u00e4 ja kohteena ei-viraaliselle geeninsiirrolle)","author":"Pitk\u00e4nen","year":"2007","journal-title":"Kuopion yliopisto"},{"key":"10.1016\/j.jconrel.2026.114841_bb0275","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1177\/24741264211028441","article-title":"Intravitreal injection therapy: current techniques and supplemental services","volume":"5","author":"Lam","year":"2021","journal-title":"J. Vitreoretin. Dis."},{"key":"10.1016\/j.jconrel.2026.114841_bb0280","doi-asserted-by":"crossref","first-page":"1700739","DOI":"10.1002\/adhm.201700739","article-title":"Preventing obstructions of nanosized drug delivery systems by the extracellular matrix","volume":"7","author":"Tomasetti","year":"2018","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2026.114841_bb0285","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1208\/s12248-017-0128-y","article-title":"Advancements in understanding immunogenicity of biotherapeutics in the intraocular space","volume":"19","author":"Wakshull","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2026.114841_bb0290","series-title":"Studies of RPE as an Immune Privileged Tissue and as the creator of Immune Privilege in the Subretinal Space","author":"Zamiri","year":"2004"},{"key":"10.1016\/j.jconrel.2026.114841_bb0295","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000479157","article-title":"Subretinal injection: a review on the novel route of therapeutic delivery for vitreoretinal diseases","volume":"58","author":"Peng","year":"2017","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.jconrel.2026.114841_bb0300","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.4103\/1673-5374.306063","article-title":"The future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery","volume":"16","author":"Ross","year":"2021","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.jconrel.2026.114841_bb0305","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000431143","article-title":"Routes for drug delivery to the eye and retina: intravitreal injections","volume":"55","author":"Meyer","year":"2016","journal-title":"Retinal Pharmacother"},{"key":"10.1016\/j.jconrel.2026.114841_bb0310","doi-asserted-by":"crossref","first-page":"10535","DOI":"10.3390\/ijms241310535","article-title":"The role of subretinal injection in ophthalmic surgery: therapeutic agent delivery and other indications","volume":"24","author":"Tripepi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb0315","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13070967","article-title":"Drug delivery via the suprachoroidal space for the treatment of retinal diseases","volume":"13","author":"Naftali Ben Haim","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114841_bb0320","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/aos.14042","article-title":"Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach","volume":"97","author":"Habot-Wilner","year":"2019","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.jconrel.2026.114841_bb0325","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/bs.pmbts.2024.08.003","article-title":"Delivery of therapeutic proteins to ocular tissues: barriers, approaches, regulatory considerations and future perspectives","volume":"212","author":"Shastri","year":"2025","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb0330","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s13346-022-01231-5","article-title":"Ocular barriers as a double-edged sword: preventing and facilitating drug delivery to the retina","volume":"13","author":"Wang","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2026.114841_bb0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/smll.202307618","article-title":"Comparative analysis of PEG-free and PEG-based self-emulsifying drug delivery systems for enhanced oral bioavailability of therapeutic (poly) peptides","volume":"20","author":"Haddadzadegan","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2026.114841_bb0340","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-016-0339-2","article-title":"A comprehensive insight on ocular pharmacokinetics","volume":"6","author":"Agrahari","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2026.114841_bb0345","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3390\/pharmaceutics11080365","article-title":"Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration","volume":"11","author":"Garc\u00eda-Quintanilla","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114841_bb0350","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1089\/jop.1997.13.445","article-title":"Drug distribution in the vitreous humor of the human eye: the effects of aphakia and changes in retinal permeability and vitreous diffusivity","volume":"13","author":"Friedrich","year":"1997","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2026.114841_bb0355","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2174\/1874364101004010052","article-title":"Aqueous humor dynamics: a review","volume":"4","author":"Goel","year":"2010","journal-title":"Open Ophthalmol. J."},{"key":"10.1016\/j.jconrel.2026.114841_bb0360","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/pharmaceutics11010009","article-title":"Pharmacokinetic simulations of intravitreal biologicals: aspects of drug delivery to the posterior and anterior segments","volume":"11","author":"Rimpel\u00e4","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114841_bb0365","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"Del Amo","year":"2017","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2026.114841_bb0370","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1167\/iovs.16-20377","article-title":"Thickness and closure kinetics of the suprachoroidal space following microneedle injection of liquid formulations","volume":"58","author":"Chiang","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb0375","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1167\/iovs.16-20679","article-title":"Clearance kinetics and clearance routes of molecules from the suprachoroidal space after microneedle injection","volume":"58","author":"Chiang","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb0380","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adl3576","article-title":"Suprachoroidal gene transfer with nonviral nanoparticles in large animal eyes","volume":"10","author":"Shen","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.114841_bb0385","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jconrel.2019.06.042","article-title":"Non-viral delivery of chemically modified mRNA to the retina: subretinal versus intravitreal administration","volume":"307","author":"Devoldere","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114841_bb0390","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.nano.2015.04.015","article-title":"Size, surface charge, and shape determine therapeutic effects of nanoparticles on brain and retinal diseases","volume":"11","author":"Jo","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.114841_bb0395","series-title":"Intravitreal Liposomes as Ocular Drug Delivery Systems: Vitreal Interactions, Retinal Permeation and Drug Release Characteristics, Dissertationes Scholae Doctoralis ad Sanitatem Investigandam Universitatis Helsinkiensis","author":"Tavakoli","year":"2021"},{"key":"10.1016\/j.jconrel.2026.114841_bb0400","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1039\/D3NH00306J","article-title":"Enhancing paracellular and transcellular permeability using nanotechnological approaches for the treatment of brain and retinal diseases","volume":"9","author":"Khalil","year":"2024","journal-title":"Nanoscale Horiz."},{"key":"10.1016\/j.jconrel.2026.114841_bb0405","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1167\/iovs.11-8502","article-title":"Nanoscale topographic and biomechanical studies of the human internal limiting membrane","volume":"53","author":"Henrich","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb0410","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/02713683.2019.1565890","article-title":"Morphology and composition of the inner limiting membrane: species-specific variations and relevance toward drug delivery research","volume":"44","author":"Peynshaert","year":"2019","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.jconrel.2026.114841_bb0415","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3390\/pharmaceutics13071013","article-title":"Investigating ex vivo animal models to test the performance of intravitreal liposomal drug delivery systems","volume":"13","author":"Christensen","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114841_bb0420","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jconrel.2020.10.028","article-title":"Ocular barriers to retinal delivery of intravitreal liposomes: impact of vitreoretinal interface","volume":"328","author":"Tavakoli","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114841_bb0425","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jconrel.2013.01.018","article-title":"Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo","volume":"167","author":"Xu","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114841_bb0430","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11051-020-04785-y","article-title":"Effect of particle size and surface charge of nanoparticles in penetration through intestinal mucus barrier","volume":"22","author":"Bandi","year":"2020","journal-title":"J. Nanopart. Res."},{"key":"10.1016\/j.jconrel.2026.114841_bb0435","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1021\/acsomega.3c08836","article-title":"Enhanced mucoadhesion of thiolated \u03b2-cyclodextrin by S-protection with 2-mercaptoethanesulfonic acid","volume":"9","author":"Kali","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.jconrel.2026.114841_bb0440","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00109-022-02208-0","article-title":"Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective","volume":"100","author":"S. Jt","year":"2022","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.jconrel.2026.114841_bb0445","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.114841_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005569","article-title":"Adenovirus dodecahedron, as a drug delivery vector","volume":"4","author":"Zochowska","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2026.114841_bb0455","series-title":"Viral Infections of Humans: Epidemiology and Control","first-page":"1","article-title":"Adenoviruses","author":"Lu","year":"2023"},{"key":"10.1016\/j.jconrel.2026.114841_bb0460","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2144\/btn-2022-0051","article-title":"Adenovirus vector system: construction, history and therapeutic applications","volume":"73","author":"Syyam","year":"2022","journal-title":"Biotechniques"},{"key":"10.1016\/j.jconrel.2026.114841_bb0465","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3390\/pharmaceutics13101585","article-title":"The revolving door of adenovirus cell entry: not all pathways are equal","volume":"13","author":"Nesti\u0107","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114841_bb0470","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.114841_bb0475","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10258","article-title":"Viral vector-based gene therapies in the clinic","volume":"7","author":"Zhao","year":"2022","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.114841_bb0480","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1128\/jvi.70.6.4173-4178.1996","article-title":"Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy","volume":"70","author":"Gorziglia","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2026.114841_bb0485","doi-asserted-by":"crossref","first-page":"6196","DOI":"10.1073\/pnas.91.13.6196","article-title":"Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver","volume":"91","author":"Engelhardt","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2026.114841_bb0490","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.gt.3302612","article-title":"Gutless adenovirus: last-generation adenovirus for gene therapy","volume":"12","author":"Alba","year":"2005","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114841_bb0495","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-021-00356-x","article-title":"Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic","volume":"6","author":"Mendon\u00e7a","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.jconrel.2026.114841_bb0500","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.114841_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105834","article-title":"Viral and non-viral vectors in gene therapy: current state and clinical perspectives","volume":"118","author":"Geng","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jconrel.2026.114841_bb0510","series-title":"Capsid Assembly and Single Stranded DNA Genome Formation of Adeno-Associated Virus Type2 in Yeast Cells","author":"Backovic","year":"2011"},{"key":"10.1016\/j.jconrel.2026.114841_bb0515","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JVI.00773-21","article-title":"Improved genome packaging efficiency of adeno-associated virus vectors using rep hybrids","volume":"95","author":"Mietzsch","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2026.114841_bb0520","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3390\/v16081215","article-title":"The expression and function of the small nonstructural proteins of adeno-associated viruses (AAVs)","volume":"16","author":"Kuz","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.jconrel.2026.114841_bb0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/jvi.00637-25","article-title":"Retinal transduction profiling of diverse AAV serotypes via intravitreal injection","volume":"99","author":"Zhang","year":"2025","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2026.114841_bb0530","doi-asserted-by":"crossref","first-page":"1148795","DOI":"10.3389\/fddev.2023.1148795","article-title":"AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery","volume":"3","author":"Koponen","year":"2023","journal-title":"Front. Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.114841_bb0535","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1016\/j.ymthe.2022.09.015","article-title":"AAV vectors: the Rubik\u2019s cube of human gene therapy","volume":"30","author":"Pupo","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.114841_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101469","article-title":"Redosing of AAV vectors in the brain after intracranial injections: low-ish hanging fruit?","volume":"33","author":"Maguire","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2026.114841_bb0545","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1607","article-title":"Optimization strategies and advances in the research and development of AAV-based gene therapy to deliver large transgenes","volume":"14","author":"Kolesnik","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.jconrel.2026.114841_bb0550","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adv7922","article-title":"Retinal gene therapy using epiretinal AAV-containing fibrin hydrogel implants","volume":"11","author":"Scruggs","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.114841_bb0555","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.3390\/v13071288","article-title":"Lentiviral vectors for delivery of gene-editing systems based on CRISPR\/Cas: current state and perspectives","volume":"13","author":"Dong","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jconrel.2026.114841_bb0560","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1167\/iovs.64.7.39","article-title":"Gene therapy for retinal degenerative diseases: progress, challenges, and future directions","volume":"64","author":"Drag","year":"2023","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb0565","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/v14020324","article-title":"Visualization of retroviral gag-genomic RNA cellular interactions leading to genome encapsidation and viral assembly: An overview","volume":"14","author":"Bernacchi","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.jconrel.2026.114841_bb0570","doi-asserted-by":"crossref","first-page":"542","DOI":"10.4103\/NRR.NRR-D-24-00797","article-title":"Innovative gene delivery systems for retinal disease therapy","volume":"21","author":"Wu","year":"2026","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.jconrel.2026.114841_bb0575","series-title":"Retinal Degenerative Diseases","first-page":"255","article-title":"Gene delivery to the retina using lentiviral vectors","author":"Greenberg","year":"2006"},{"key":"10.1016\/j.jconrel.2026.114841_bb0580","article-title":"The effect of enhancers on the lentiviral transduction efficiency in the human RPE cells: insights for advancing retinal gene therapies","volume":"42","author":"Najafi","year":"2025","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.jconrel.2026.114841_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2021.101142","article-title":"Role of nanotechnology behind the success of mRNA vaccines for COVID-19","volume":"38","author":"Khurana","year":"2021","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2026.114841_bb0590","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens13060500","article-title":"Brief insights into mRNA vaccines: their successful production and nanoformulation for effective response against COVID-19 and their potential success for influenza a and B","volume":"13","author":"Parveen","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.jconrel.2026.114841_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114097","article-title":"Oral delivery of therapeutic peptides and proteins: technology landscape of lipid-based nanocarriers","volume":"182","author":"Haddadzadegan","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2026.114841_bb0600","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/adfm.202500157","article-title":"Intraoral drug delivery: bridging the gap between academic research and industrial innovations","volume":"35","author":"Haddadzadegan","year":"2025","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2026.114841_bb0605","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1007\/s13346-024-01538-5","article-title":"Design of charge converting lipid nanoparticles via a microfluidic coating technique","volume":"14","author":"Z\u00f6ller","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2026.114841_bb0610","doi-asserted-by":"crossref","first-page":"6797","DOI":"10.1021\/acsbiomaterials.3c01207","article-title":"Power-up for mucoadhesiveness: two generations of thiolated surfactants for enhanced sticky nanoemulsions","volume":"9","author":"To","year":"2023","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.jconrel.2026.114841_bb0615","first-page":"1","article-title":"Liquid crystalline inverted lipid phases and reverse micelles in drug delivery: from molecular design to therapeutic potential","author":"Eczacioglu","year":"2025","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2026.114841_bb0620","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics9020012","article-title":"Liposomal formulations in clinical use: an updated review","volume":"9","author":"Bulbake","year":"2017","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114841_bb0625","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae\u2014the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114841_bb0630","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00441-019-03001-1","article-title":"Intravitreal Ets1 siRNA alleviates choroidal neovascularization in a mouse model of age-related macular degeneration","volume":"376","author":"Zhu","year":"2019","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.jconrel.2026.114841_bb0635","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.7150\/thno.15230","article-title":"Cell-specific promoters enable lipid-based nanoparticles to deliver genes to specific cells of the retina in vivo","volume":"6","author":"Wang","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2026.114841_bb0640","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jconrel.2019.04.015","article-title":"Lipid nanoparticles for delivery of messenger RNA to the back of the eye","volume":"303","author":"Patel","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114841_bb0645","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3390\/nano11061508","article-title":"Use of protamine in nanopharmaceuticals\u2014a review","volume":"11","author":"Ruseska","year":"2021","journal-title":"Nanomaterials"},{"key":"10.1016\/j.jconrel.2026.114841_bb0650","series-title":"Protamine-Oligonucleotide-Nanoparticles as Depot Formulation, Targeting System and Immune-Modulator\/Mag. Pharm. Bernhard Scheicher","author":"Scheicher","year":"2026"},{"key":"10.1016\/j.jconrel.2026.114841_bb0655","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fphar.2020.00697","article-title":"Cell-penetrating peptides in diagnosis and treatment of human diseases: from preclinical research to clinical application","volume":"11","author":"Xie","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.114841_bb0660","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1038\/s41467-023-42189-3","article-title":"Lipid nanoparticles with PEG-variant surface modifications mediate genome editing in the mouse retina","volume":"14","author":"Gautam","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114841_bb0665","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ymthe.2019.09.010","article-title":"Non-viral gene therapy for Stargardt disease with ECO\/pRHO-ABCA4 self-assembled nanoparticles","volume":"28","author":"Sun","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.114841_bb0670","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.omtn.2022.08.026","article-title":"Effective gene therapy of Stargardt disease with PEG-ECO\/pGRK1-ABCA4-S\/MAR nanoparticles","volume":"29","author":"Sun","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2026.114841_bb0675","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.114841_bb0680","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm7950","article-title":"In vivo mRNA delivery to virus-specific T cells by light-induced ligand exchange of MHC class I antigen-presenting nanoparticles","volume":"8","author":"Su","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.114841_bb0685","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add4623","article-title":"Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates","volume":"9","author":"Herrera-Barrera","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.114841_bb0690","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ejpb.2011.06.005","article-title":"Understanding the mechanism of protamine in solid lipid nanoparticle-based lipofection: the importance of the entry pathway","volume":"79","author":"Delgado","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.114841_bb0695","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/hum.2011.115","article-title":"Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X-linked juvenile retinoschisis","volume":"23","author":"Delgado","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2026.114841_bb0700","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijpharm.2014.02.038","article-title":"A novel gene therapy vector based on hyaluronic acid and solid lipid nanoparticles for ocular diseases","volume":"465","author":"Apaolaza","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.114841_bb0705","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1167\/iovs.10-5891","article-title":"A lipid nanoparticle system improves siRNA efficacy in RPE cells and a laser-induced murine CNV model","volume":"52","author":"Liu","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb0710","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.nano.2018.12.018","article-title":"Non-viral vectors based on cationic niosomes and minicircle DNA technology enhance gene delivery efficiency for biomedical applications in retinal disorders","volume":"17","author":"Gallego","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.114841_bb0715","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1167\/tvst.13.7.7","article-title":"Lipid nanoparticle-mediated delivery of mRNA into the mouse and human retina and other ocular tissues","volume":"13","author":"Chambers","year":"2024","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.jconrel.2026.114841_bb0720","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241006","article-title":"The effects of PEGylation on LNP based mRNA delivery to the eye","volume":"15","author":"Ryals","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2026.114841_bb0725","doi-asserted-by":"crossref","first-page":"2400815","DOI":"10.1002\/smll.202400815","article-title":"Preformed vesicle approach to LNP manufacturing enhances retinal mRNA delivery","volume":"20","author":"Eygeris","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2026.114841_bb0730","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1021\/acs.molpharmaceut.0c00992","article-title":"Enhanced delivery of siRNA to retinal ganglion cells by intravitreal lipid nanoparticles of positive charge","volume":"18","author":"Huang","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2026.114841_bb0735","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jconrel.2019.02.014","article-title":"Co-delivery of miR-181a and melphalan by lipid nanoparticles for treatment of seeded retinoblastoma","volume":"298","author":"Tabatabaei","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114841_bb0740","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.3390\/ijms22052318","article-title":"The landscape of non-viral gene augmentation strategies for inherited retinal diseases","volume":"22","author":"Toualbi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb0745","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1208\/s12248-021-00608-7","article-title":"Non-viral vectors in gene therapy: recent development, challenges, and prospects","volume":"23","author":"Zu","year":"2021","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2026.114841_bb0750","doi-asserted-by":"crossref","first-page":"11043","DOI":"10.1021\/cr5006793","article-title":"Nucleic acid therapeutics using polyplexes: a journey of 50 years (and beyond)","volume":"115","author":"L\u00e4chelt","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2026.114841_bb0755","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1021\/acs.biomac.2c00767","article-title":"Designing synthetic polymers for nucleic acid complexation and delivery: from polyplexes to Micelleplexes to triggered degradation","volume":"23","author":"Zhou","year":"2022","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2026.114841_bb0760","first-page":"1","article-title":"Payload-driven design of polymeric carriers for nucleic acid delivery: insights from structure\u2013function relationships","volume":"13","author":"Moradian","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb0765","doi-asserted-by":"crossref","first-page":"7147","DOI":"10.1039\/c2cs35094g","article-title":"Cationic polymers and their therapeutic potential","volume":"41","author":"Samal","year":"2012","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2026.114841_bb0770","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3390\/pharmaceutics16070868","article-title":"Gene therapy with chitosan nanoparticles: modern formulation strategies for enhancing cancer cell transfection","volume":"16","author":"Antoniou","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114841_bb0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2021.112219","article-title":"New insights on the mechanism of polyethylenimine transfection and their implications on gene therapy and DNA vaccines","volume":"210","author":"Sabin","year":"2022","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2026.114841_bb0780","doi-asserted-by":"crossref","first-page":"2309748","DOI":"10.1002\/advs.202309748","article-title":"Recent progress in nucleic acid pulmonary delivery toward overcoming physiological barriers and improving transfection efficiency","volume":"11","author":"Wang","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb0785","first-page":"1","article-title":"Advancing engineering design strategies for targeted cancer nanomedicine","author":"Gomerdinger","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.114841_bb0790","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/jnt6020010","article-title":"Nanotheranostics revolutionizing gene therapy: emerging applications in gene delivery enhancement","volume":"6","author":"Guzm\u00e1n-Sastoque","year":"2025","journal-title":"J. Nanotheranostics"},{"key":"10.1016\/j.jconrel.2026.114841_bb0795","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2174\/1381612822666151216151420","article-title":"Journey to the center of the cell: current nanocarrier design strategies targeting biopharmaceuticals to the cytoplasm and nucleus","volume":"22","author":"Munsell","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2026.114841_bb0800","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1039\/C8TB00967H","article-title":"The great escape: how cationic polyplexes overcome the endosomal barrier","volume":"6","author":"Bus","year":"2018","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2026.114841_bb0805","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejpb.2018.05.034","article-title":"The proton sponge hypothesis: fable or fact?","volume":"129","author":"Vermeulen","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.114841_bb0810","doi-asserted-by":"crossref","first-page":"6967","DOI":"10.1039\/c1sm05449j","article-title":"Formation and structure of PEI\/DNA complexes: quantitative analysis","volume":"7","author":"Hou","year":"2011","journal-title":"Soft Matter"},{"key":"10.1016\/j.jconrel.2026.114841_bb0815","series-title":"Polymeric Gene Delivery Systems","first-page":"41","article-title":"Polymer\u2013nucleic acid interactions","author":"Shen","year":"2017"},{"key":"10.1016\/j.jconrel.2026.114841_bb0820","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1021\/acsnano.7b07583","article-title":"Endosomal size and membrane leakiness influence proton sponge-based rupture of endosomal vesicles","volume":"12","author":"Vermeulen","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114841_bb0825","series-title":"Molecular Regulation of Endocytosis","first-page":"429","article-title":"Endosomal escape pathways for non-viral nucleic acid delivery systems","author":"Liang","year":"2012"},{"key":"10.1016\/j.jconrel.2026.114841_bb0830","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.3390\/polym16182629","article-title":"Polymers as efficient non-viral gene delivery vectors: the role of the chemical and physical architecture of macromolecules","volume":"16","author":"Khan","year":"2024","journal-title":"Polymers (Basel)."},{"key":"10.1016\/j.jconrel.2026.114841_bb0835","doi-asserted-by":"crossref","DOI":"10.3390\/life13040903","article-title":"Non-viral carriers for nucleic acids delivery: fundamentals and current applications","volume":"13","author":"Shtykalova","year":"2023","journal-title":"Life"},{"key":"10.1016\/j.jconrel.2026.114841_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e26616","article-title":"Light-responsive polymeric nanoparticles for retinal drug delivery: design cues, challenges and future perspectives","volume":"10","author":"Guidi","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.jconrel.2026.114841_bb0845","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/BF01687366","article-title":"Effects of alkaline phosphatase inhibitors on chick neural retinal cell differentiation in vitro: ultracytochemical studies","volume":"19","author":"Araki","year":"1987","journal-title":"Histochem. J."},{"key":"10.1016\/j.jconrel.2026.114841_bb0850","doi-asserted-by":"crossref","first-page":"44981","DOI":"10.1021\/acsami.2c11649","article-title":"Charge-converting nanoemulsions as promising retinal drug and gene delivery systems","volume":"14","author":"Nguyen Le","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2026.114841_bb0855","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ejpb.2014.12.028","article-title":"Nanoparticle-based technologies for retinal gene therapy","volume":"95","author":"Adijanto","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2026.114841_bb0860","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.preteyeres.2010.04.004","article-title":"Nanoparticles for retinal gene therapy","volume":"29","author":"Conley","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.jconrel.2026.114841_bb0865","first-page":"466","article-title":"The role of cell cycle on polyplex-mediated gene transfer into a retinal pigment epithelial cell line","volume":"7","author":"M\u00e4nnist\u00f6","year":"2005","journal-title":"J. Gene Med. Cross Discipl. J. Res. Sci. Gene Transf. Clin. Appl."},{"key":"10.1016\/j.jconrel.2026.114841_bb0870","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3390\/md20050335","article-title":"Multiple roles of chitosan in mucosal drug delivery: an updated review","volume":"20","author":"Mura","year":"2022","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.jconrel.2026.114841_bb0875","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.3390\/pharmaceutics13101685","article-title":"Posterior segment ophthalmic drug delivery: role of muco-adhesion with a special focus on chitosan","volume":"13","author":"Burhan","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114841_bb0880","series-title":"Chitosan-Based Formulations for Enhanced Topical, Transdermal, and Ocular Drug Delivery","author":"Hmingthansanga","year":"2025"},{"key":"10.1016\/j.jconrel.2026.114841_bb0885","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ejps.2012.11.009","article-title":"Oligochitosan polyplexes as carriers for retinal gene delivery","volume":"48","author":"Puras","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb0890","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/cmdc.201300371","article-title":"Synthesis and characterization of glycol chitosan DNA nanoparticles for retinal gene delivery","volume":"9","author":"Mitra","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jconrel.2026.114841_bb0895","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3390\/pharmaceutics15051502","article-title":"Cationic polymers as transfection reagents for nucleic acid delivery","volume":"15","author":"Cai","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114841_bb0900","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3390\/pharmaceutics17070927","article-title":"From structure to function: the promise of PAMAM dendrimers in biomedical applications","volume":"17","author":"Alamos-Musre","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114841_bb0905","doi-asserted-by":"crossref","first-page":"2203629","DOI":"10.1002\/smll.202203629","article-title":"Polymeric dendrimers as nanocarrier vectors for neurotheranostics","volume":"18","author":"Li","year":"2022","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2026.114841_bb0910","doi-asserted-by":"crossref","first-page":"590","DOI":"10.2174\/1567201812666150817123049","article-title":"Efficient siRNA delivery using PEG-conjugated PAMAM dendrimers targeting vascular endothelial growth factor in a CoCl2-induced neovascularization model in retinal endothelial cells","volume":"13","author":"Xu","year":"2016","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.114841_bb0915","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.actbio.2021.07.053","article-title":"A core-shell nanoplatform as a nonviral vector for targeted delivery of genes to the retina","volume":"134","author":"Tan","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2026.114841_bb0920","doi-asserted-by":"crossref","DOI":"10.1016\/j.colcom.2022.100647","article-title":"Hyperbranched-star PEI-g-PEG as a nonviral vector with efficient uptake and hypotoxicity for retinoblastoma gene therapy application","volume":"50","author":"Wang","year":"2022","journal-title":"Colloid Interface Sci. Commun."},{"key":"10.1016\/j.jconrel.2026.114841_bb0925","article-title":"Non-viral gene therapy using RNA interference with PDGFR-\u03b1 mediated epithelial-mesenchymal transformation for proliferative vitreoretinopathy","volume":"20","author":"Wang","year":"2023","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.jconrel.2026.114841_bb0930","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1248\/bpb.b12-00728","article-title":"Ocular gene delivery systems using ternary complexes of plasmid DNA, polyethylenimine, and anionic polymers","volume":"36","author":"Kurosaki","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2026.114841_bb0935","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0168-3659(02)00178-5","article-title":"Structure\u2013activity relationships of poly (l-lysines): effects of pegylation and molecular shape on physicochemical and biological properties in gene delivery","volume":"83","author":"M\u00e4nnist\u00f6","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114841_bb0940","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1039\/C4NR04284K","article-title":"Hydroxyl PAMAM dendrimer-based gene vectors for transgene delivery to human retinal pigment epithelial cells","volume":"7","author":"Mastorakos","year":"2015","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2026.114841_bb0945","doi-asserted-by":"crossref","first-page":"19256","DOI":"10.1021\/acsami.6b04551","article-title":"Facile noninvasive retinal gene delivery enabled by penetratin","volume":"8","author":"Liu","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2026.114841_bb0950","series-title":"Chitosan-based vectors mediate long-term gene expression in the retina","author":"Oliveira12","year":"2015"},{"key":"10.1016\/j.jconrel.2026.114841_bb0955","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2025.102920","article-title":"Rational design of extracellular vesicles for targeted drug delivery across physiological barriers","volume":"66","author":"Baby","year":"2026","journal-title":"Nano Today"},{"key":"10.1016\/j.jconrel.2026.114841_bb0960","doi-asserted-by":"crossref","first-page":"10519","DOI":"10.2147\/IJN.S277190","article-title":"Roles of exosomes in ocular diseases","author":"Liu","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2026.114841_bb0965","doi-asserted-by":"crossref","first-page":"22793","DOI":"10.1021\/acsnano.4c08486","article-title":"Advances in extracellular-vesicles-based diagnostic and therapeutic approaches for ocular diseases","volume":"18","author":"Su","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114841_bb0970","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1039\/D2NH00070A","article-title":"Engineered extracellular vesicles as intelligent nanosystems for next-generation nanomedicine","volume":"7","author":"Fan","year":"2022","journal-title":"Nanoscale Horiz."},{"key":"10.1016\/j.jconrel.2026.114841_bb0975","series-title":"Evidence-based clinical use of nanoscale extracellular vesicles in nanomedicine, Perspective","author":"Fais","year":"2016"},{"key":"10.1016\/j.jconrel.2026.114841_bb0980","doi-asserted-by":"crossref","first-page":"7568","DOI":"10.3390\/ijms21207568","article-title":"Tetraspanins, more than markers of extracellular vesicles in reproduction","volume":"21","author":"Jankovi\u010dov\u00e1","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb0985","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12964-021-00730-1","article-title":"The exosome journey: from biogenesis to uptake and intracellular signalling","volume":"19","author":"Gurung","year":"2021","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.jconrel.2026.114841_bb0990","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s11010-023-04798-w","article-title":"Potential in exosome-based targeted nano-drugs and delivery vehicles for posterior ocular disease treatment: from barriers to therapeutic application","volume":"479","author":"Peng","year":"2024","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.jconrel.2026.114841_bb0995","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/s12951-025-03589-3","article-title":"Recent advances in engineered exosome-based therapies for ocular vascular disease","volume":"23","author":"Guan","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2026.114841_bb1000","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1007\/s13346-021-01087-1","article-title":"Exosomal targeting and its potential clinical application","volume":"12","author":"He","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2026.114841_bb1005","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.bbalip.2013.10.004","article-title":"Exosomes as new vesicular lipid transporters involved in cell\u2013cell communication and various pathophysiologies","volume":"1841","author":"Record","year":"2014","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.jconrel.2026.114841_bb1010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12929-024-01036-3","article-title":"Contribution of extracellular vesicles for the pathogenesis of retinal diseases: shedding light on blood-retinal barrier dysfunction","volume":"31","author":"Martins","year":"2024","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb1015","article-title":"Emerging role of exosomes in retinal diseases","volume":"9","author":"Zhang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.jconrel.2026.114841_bb1020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s10020-025-01120-w","article-title":"Mesenchymal stem cells and mesenchymal stem cell-derived exosomes: a promising strategy for treating retinal degenerative diseases","volume":"31","author":"An","year":"2025","journal-title":"Mol. Med."},{"key":"10.1016\/j.jconrel.2026.114841_bb1025","doi-asserted-by":"crossref","first-page":"8883616","DOI":"10.1155\/2020\/8883616","article-title":"Effect of mesenchymal stem cell-derived exosomes on retinal injury: a review of current findings","volume":"2020","author":"Nuzzi","year":"2020","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.jconrel.2026.114841_bb1030","doi-asserted-by":"crossref","first-page":"7384","DOI":"10.1039\/D4TB00849A","article-title":"Cationic-motif-modified exosomes for mRNA delivery to retinal photoreceptors","volume":"12","author":"Cotto","year":"2024","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2026.114841_bb1035","doi-asserted-by":"crossref","first-page":"1487627","DOI":"10.3389\/fbioe.2025.1487627","article-title":"Advancements in extracellular vesicles biomanufacturing: a comprehensive overview of large-scale production and clinical research","volume":"13","author":"Li","year":"2025","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.114841_bb1040","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.3390\/polym13193307","article-title":"Application of non-viral vectors in drug delivery and gene therapy","volume":"13","author":"Ren","year":"2021","journal-title":"Polymers (Basel)."},{"key":"10.1016\/j.jconrel.2026.114841_bb1045","doi-asserted-by":"crossref","first-page":"7918","DOI":"10.3390\/ijms26167918","article-title":"Applications of tailored mesoporous silicate nanomaterials in regenerative medicine and Theranostics","volume":"26","author":"Fotie","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb1050","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jconrel.2022.08.006","article-title":"Immunomodulation of MiRNA-223-based nanoplatform for targeted therapy in retinopathy of prematurity","volume":"350","author":"Huang","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114841_bb1055","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.3390\/jcm11082170","article-title":"Mesoporous silica-based nanoparticles as non-viral gene delivery platform for treating retinitis pigmentosa","volume":"11","author":"Vald\u00e9s-S\u00e1nchez","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2026.114841_bb1060","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jconrel.2021.06.030","article-title":"In vivo targeted delivery of nucleic acids and CRISPR genome editors enabled by GSH-responsive silica nanoparticles","volume":"336","author":"Wang","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114841_bb1065","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jconrel.2020.04.052","article-title":"A pH-responsive silica\u2013metal\u2013organic framework hybrid nanoparticle for the delivery of hydrophilic drugs, nucleic acids, and CRISPR-Cas9 genome-editing machineries","volume":"324","author":"Wang","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2026.114841_bb1070","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2021.110519","article-title":"Vitreous collagen cross-linking and maturation and interactions with internal limiting membrane (ILM) collagen may have a potential role in modulating postnatal growth of the eyeball","volume":"148","author":"Venkatesh","year":"2021","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.jconrel.2026.114841_bb1075","series-title":"Microscopic Structure of the Retina and Vasculature in the Human Eye, Microscopy: Science, Technology, Applications and Education","first-page":"875","volume":"867","author":"Yu","year":"2010"},{"key":"10.1016\/j.jconrel.2026.114841_bb1080","first-page":"1661","article-title":"The relationship between pore density and outflow facility in human eyes","volume":"33","author":"Allingham","year":"1992","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb1085","series-title":"Understanding the Role of Electrostatic Force, Van der Waals Force, and Osmotic Pressure in Retinal Function and Barrier Integrity","author":"Karaja","year":"2025"},{"key":"10.1016\/j.jconrel.2026.114841_bb1090","first-page":"1","article-title":"Nanostructured drug delivery systems for posterior segment eye diseases: strategies to defy ocular barriers","author":"Shen","year":"2025","journal-title":"BMEMat"},{"key":"10.1016\/j.jconrel.2026.114841_bb1095","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/nano13010002","article-title":"From ionic nanoparticle organic hybrids to ionic nanocomposites: structure, dynamics, and properties: a review","volume":"13","author":"Karatrantos","year":"2022","journal-title":"Nanomaterials"},{"key":"10.1016\/j.jconrel.2026.114841_bb1100","article-title":"Intraocular drug delivery systems for diabetic retinopathy: current and future prospective","volume":"15","author":"Taheri","year":"2024","journal-title":"Bioimpacts"},{"key":"10.1016\/j.jconrel.2026.114841_bb1105","doi-asserted-by":"crossref","first-page":"2314126","DOI":"10.1002\/adma.202314126","article-title":"Enhanced ocular delivery of Beva via ultra-small polymeric micelles for noninvasive anti-VEGF therapy","volume":"36","author":"Yang","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.114841_bb1110","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.apsb.2023.09.001","article-title":"pH-responsive polymer boosts cytosolic siRNA release for retinal neovascularization therapy","volume":"14","author":"Guo","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2026.114841_bb1115","doi-asserted-by":"crossref","first-page":"7299","DOI":"10.1007\/s11696-025-04315-x","article-title":"Nanostructure colloids in ocular drug delivery: advances and challenges","volume":"79","author":"Khaledian","year":"2025","journal-title":"Chem. Pap."},{"key":"10.1016\/j.jconrel.2026.114841_bb1120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12088-024-01304-8","article-title":"Mucus-penetrating PEGylated Nanoshuttle for enhanced drug delivery and healthcare applications","volume":"65","author":"Bain","year":"2025","journal-title":"Indian J. Microbiol."},{"key":"10.1016\/j.jconrel.2026.114841_bb1125","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.3390\/cells13201706","article-title":"A comparative analysis of models for AAV-mediated gene therapy for inherited retinal diseases","volume":"13","author":"Alsalloum","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2026.114841_bb1130","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1016\/j.ymthe.2024.10.017","article-title":"Recombinant adeno-associated virus as a delivery platform for ocular gene therapy: a comprehensive review","volume":"32","author":"Wang","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.114841_bb1135","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.3390\/bioengineering12101122","article-title":"Surgical approaches to retinal gene therapy: 2025 update","volume":"12","author":"Patel","year":"2025","journal-title":"Bioengineering"},{"key":"10.1016\/j.jconrel.2026.114841_bb1140","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1089\/hum.2017.179","article-title":"Assessment of adeno-associated virus serotype tropism in human retinal explants","volume":"29","author":"Wiley","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2026.114841_bb1145","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.omtm.2023.05.016","article-title":"In-depth comparison of Anc80L65 and AAV9 retinal targeting and characterization of cross-reactivity to multiple AAV serotypes in humans","volume":"30","author":"Schwartz","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2026.114841_bb1150","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.3390\/ijms21124197","article-title":"Recombinant adeno-associated viral vectors (rAAV)-vector elements in ocular gene therapy clinical trials and transgene expression and bioactivity assays","volume":"21","author":"Buck","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb1155","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.omtm.2020.03.003","article-title":"Empowering retinal gene therapy with a specific promoter for human rod and cone ON-bipolar cells","volume":"17","author":"Hulliger","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2026.114841_bb1160","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.drudis.2019.05.038","article-title":"Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives","volume":"24","author":"Bordet","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2026.114841_bb1165","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/mt.2009.319","article-title":"Recent advances in lentiviral vector development and applications","volume":"18","author":"M\u00e1trai","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.114841_bb1170","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/mt.2012.244","article-title":"Minicircle DNA vectors achieve sustained expression reflected by active chromatin and transcriptional level","volume":"21","author":"Maniar","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.114841_bb1175","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1006\/mthe.2001.0333","article-title":"Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo","volume":"3","author":"Miao","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.114841_bb1180","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20160616","article-title":"Cytoplasmic transport and nuclear import of plasmid DNA","volume":"37","author":"Bai","year":"2017","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.jconrel.2026.114841_bb1185","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.omtm.2022.02.011","article-title":"Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations","volume":"25","author":"Mendell","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2026.114841_bb1190","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1177\/10430342251378524","article-title":"Pre-existing anti-adeno-associated virus immunity in gene therapy: mechanisms, challenges, and potential solutions","volume":"36","author":"Iroanya","year":"2025","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2026.114841_bb1195","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.3390\/pharmaceutics17111492","article-title":"Emerging technologies tackling adeno-associated viruses (AAV) immunogenicity in gene therapy applications","volume":"17","author":"Egorova","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2026.114841_bb1200","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2026.114841_bb1205","article-title":"A versatile toolkit for overcoming AAV immunity","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.114841_bb1210","first-page":"3785","article-title":"Safety and efficacy of EDIT-101 for treatment of CEP290-associated retinal degeneration","volume":"64","author":"Pierce","year":"2023","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb1215","first-page":"2836","article-title":"Exploratory safety profile of EDIT-101, a first-in-human in vivo CRISPR gene editing therapy for CEP290-related retinal degeneration","volume":"63","author":"Jaskolka","year":"2022","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb1220","series-title":"CRISPR-Cas9 Gene Therapy Effects on Inherited Eye Disorders","author":"Pisack","year":"2025"},{"key":"10.1016\/j.jconrel.2026.114841_bb1225","doi-asserted-by":"crossref","first-page":"1553590","DOI":"10.3389\/fgeed.2025.1553590","article-title":"CRISPR-dependent base editing as a therapeutic strategy for rare monogenic disorders","volume":"7","author":"Cabr\u00e9-Romans","year":"2025","journal-title":"Front. Genome Ed."},{"key":"10.1016\/j.jconrel.2026.114841_bb1230","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1016\/j.ymthe.2025.03.026","article-title":"Recent advances in therapeutic gene-editing technologies","volume":"33","author":"Liu","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.114841_bb1235","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkae1217","article-title":"Direct delivery of Cas-embedded cytosine base editors as ribonucleoprotein complexes for efficient and accurate editing of clinically relevant targets","volume":"53","author":"Lee","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jconrel.2026.114841_bb1240","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102622","article-title":"In vivo precision base editing to rescue mouse models of disease","volume":"36","author":"Schindeler","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2026.114841_bb1245","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/s41591-024-03422-8","article-title":"High-efficiency base editing in the retina in primates and human tissues","volume":"31","author":"Muller","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2026.114841_bb1250","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.ymthe.2020.07.021","article-title":"Current status and challenges of DNA base editing tools","volume":"28","author":"Jeong","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2026.114841_bb1255","doi-asserted-by":"crossref","first-page":"16597","DOI":"10.1021\/acsnano.3c02669","article-title":"Redox-responsive phase-separating peptide as a universal delivery vehicle for CRISPR\/Cas9 genome editing machinery","volume":"17","author":"Sun","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114841_bb1260","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1021\/jacs.4c14469","article-title":"Peptide-based complex coacervates stabilized by cation\u2212 \u03c0 interactions for cell engineering","volume":"147","author":"Sun","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2026.114841_bb1265","doi-asserted-by":"crossref","first-page":"10094","DOI":"10.1038\/s41467-024-54463-z","article-title":"Phase-separating peptide coacervates with programmable material properties for universal intracellular delivery of macromolecules","volume":"15","author":"Sun","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.114841_bb1270","doi-asserted-by":"crossref","first-page":"24724","DOI":"10.1021\/acsnano.4c16908","article-title":"Polyethylene-glycol-conjugated peptide coacervates with tunable size for intracellular mRNA delivery","volume":"19","author":"Sun","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2026.114841_bb1275","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2147\/OPTH.S364200","article-title":"Ocular gene therapy: a literature review with special focus on immune and inflammatory responses","author":"Ghoraba","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.jconrel.2026.114841_bb1280","doi-asserted-by":"crossref","DOI":"10.3390\/polym14173580","article-title":"Current advances in nano-based and polymeric stimuli-responsive drug delivery targeting the ocular microenvironment: a review and envisaged future perspectives","volume":"14","author":"Dludla","year":"2022","journal-title":"Polymers (Basel)."},{"key":"10.1016\/j.jconrel.2026.114841_bb1285","doi-asserted-by":"crossref","first-page":"1606372","DOI":"10.3389\/fphar.2025.1606372","article-title":"From basic to clinical translation: advances and perspectives of photodynamic nanodrugs","volume":"16","author":"Ma","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2026.114841_bb1290","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1242\/jcs.018036","article-title":"Integrin-dependent phagocytosis\u2013spreading from microadhesion to new concepts","volume":"121","author":"Dupuy","year":"2008","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.jconrel.2026.114841_bb1295","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.604205","article-title":"Phagocytosis by the retinal pigment epithelium: recognition, resolution, recycling","volume":"11","author":"Kwon","year":"2020","journal-title":"Front. Immunol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926002439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926002439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:55:49Z","timestamp":1779756949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926002439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":259,"alternative-id":["S0168365926002439"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114841","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retinal gene therapies for inherited ocular diseases: Translational delivery strategies from bench to bedside","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114841","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114841"}}